Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
No biomarker
Cancer:
Marginal Zone Lymphoma
Regimen:
G-CHOP (cyclophosphamide + doxorubicin hydrochloride + Gazyva (obinutuzumab) + prednisone + vincristine)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
NCCN
Excerpt:
Marginal Zone Lymphoma: Second-Line and subsequent therapy…Other recommended regimen…CHOP + obinutuzumab (category 2B)
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login